<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Proqr Therapeutics Bv — News on 6ix</title>
<link>https://6ix.com/company/proqr-therapeutics-bv</link>
<description>Latest news and press releases for Proqr Therapeutics Bv on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 08 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/proqr-therapeutics-bv" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835b0be78dffbe2df10fce2.webp</url>
<title>Proqr Therapeutics Bv</title>
<link>https://6ix.com/company/proqr-therapeutics-bv</link>
</image>
<item>
<title>ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board</title>
<link>https://6ix.com/company/proqr-therapeutics-bv/news/proqr-announces-partnership-with-ginkgo-bioworks-and-formation-of-ai-advisory-board</link>
<guid isPermaLink="true">https://6ix.com/company/proqr-therapeutics-bv/news/proqr-announces-partnership-with-ginkgo-bioworks-and-formation-of-ai-advisory-board</guid>
<pubDate>Wed, 08 Apr 2026 04:00:00 GMT</pubDate>
<description>ProQR and Ginkgo Bioworks to collaborate on autonomous lab high throughput data generation to support ProQR’s AI-enabled drug discovery for Axiomer™ProQR</description>
</item>
<item>
<title>ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026</title>
<link>https://6ix.com/company/proqr-therapeutics-bv/news/proqr-to-host-virtual-investor-and-analyst-event-highlighting-pipeline-on-april-8-2026</link>
<guid isPermaLink="true">https://6ix.com/company/proqr-therapeutics-bv/news/proqr-to-host-virtual-investor-and-analyst-event-highlighting-pipeline-on-april-8-2026</guid>
<pubDate>Wed, 25 Mar 2026 12:00:00 GMT</pubDate>
<description>LEIDEN, Netherlands & CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that it will host a virtual Investor and Analyst Event highlighting its pipeline entitled: “Expanding the Axiomer™ RNA Editing Opportunity Beyond AX-0810” Ahead of the anticipated target engagement data for AX-0810 in t</description>
</item>
<item>
<title>ProQR Announces Year End 2025 Operating and Financial Results</title>
<link>https://6ix.com/company/proqr-therapeutics-bv/news/proqr-announces-year-end-2025-operating-and-financial-results-5</link>
<guid isPermaLink="true">https://6ix.com/company/proqr-therapeutics-bv/news/proqr-announces-year-end-2025-operating-and-financial-results-5</guid>
<pubDate>Thu, 12 Mar 2026 11:00:00 GMT</pubDate>
<description>Advancing AX-0810 through ongoing Phase 1 dosing, with target engagement data expected 1H 2026Selected Development Candidates AX-2402 for Rett syndrome (MECP2, R270X) and AX-2911 for MASH (PNPLA3)Ended 2025 with € 92.4 million cash and cash equivalents and achieved $4.5 million in Eli Lilly collaboration milestones in 2025, supporting runway into mid-2027 LEIDEN, Netherlands & CAMBRIDGE, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated</description>
</item>
<item>
<title>ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference</title>
<link>https://6ix.com/company/proqr-therapeutics-bv/news/proqr-announces-webcast-of-presentation-at-the-2026-citizens-life-sciences-conference</link>
<guid isPermaLink="true">https://6ix.com/company/proqr-therapeutics-bv/news/proqr-announces-webcast-of-presentation-at-the-2026-citizens-life-sciences-conference</guid>
<pubDate>Tue, 03 Mar 2026 21:30:00 GMT</pubDate>
<description>LEIDEN, Netherlands & CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology platform, today announced that company management will present at the Citizens Life Sciences Conference on Wednesday, March 11, 2026 at 3:25pm ET. A live webcast and recording of this presentation will be available from the “Invest</description>
</item>
<item>
<title>ProQR Announces Planned Changes to Board Composition</title>
<link>https://6ix.com/company/proqr-therapeutics-bv/news/proqr-announces-planned-changes-board-130000554</link>
<guid isPermaLink="true">https://6ix.com/company/proqr-therapeutics-bv/news/proqr-announces-planned-changes-board-130000554</guid>
<pubDate>Mon, 09 Feb 2026 13:00:00 GMT</pubDate>
<description>LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that Dinko Valerio, a co-founder of the Company, and Alison Lawton will rotate off the Board at the Company’s next Annual General Meeting (AGM) as their terms conclude. The planned changes to ProQR’s Board</description>
</item>
<item>
<title>ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook</title>
<link>https://6ix.com/company/proqr-therapeutics-bv/news/proqr-announces-encouraging-ax-0810-130000980</link>
<guid isPermaLink="true">https://6ix.com/company/proqr-therapeutics-bv/news/proqr-announces-encouraging-ax-0810-130000980</guid>
<pubDate>Thu, 08 Jan 2026 13:00:00 GMT</pubDate>
<description>Initial AX-0810 data show no safety signals after 4 weeks of dosing and pharmacokinetics consistent with non-clinical data; Phase 1 enrollment and dosing in healthy volunteers ongoing with target engagement data expected in H1 2026, followed by inclusion of a patient cohortDevelopment Candidates selected for pipeline programs AX-2402 for Rett syndrome (MECP2, R270X) and AX-2911 for MASH (PNPLA3)Strategic collaboration with Eli Lilly achieved $4.5 million in milestones in 2025, contributing to st</description>
</item>
<item>
<title>ProQR to Participate in 8th Annual Evercore Healthcare Conference</title>
<link>https://6ix.com/company/proqr-therapeutics-bv/news/proqr-participate-8th-annual-evercore-130000366</link>
<guid isPermaLink="true">https://6ix.com/company/proqr-therapeutics-bv/news/proqr-participate-8th-annual-evercore-130000366</guid>
<pubDate>Mon, 01 Dec 2025 13:00:00 GMT</pubDate>
<description>LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology platform, today announced that the Company will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Thursday, December 4, 2025 at 8:20am ET. Webcast details will be accessible from the “Investors & Med</description>
</item>
<item>
<title>ProQR Announces Third Quarter 2025 Operating and Financial Results</title>
<link>https://6ix.com/company/proqr-therapeutics-bv/news/proqr-announces-third-quarter-2025-120000870</link>
<guid isPermaLink="true">https://6ix.com/company/proqr-therapeutics-bv/news/proqr-announces-third-quarter-2025-120000870</guid>
<pubDate>Thu, 06 Nov 2025 12:00:00 GMT</pubDate>
<description>Received CTA authorization for Phase 1 trial of lead program AX-0810, targeting NTCP for cholestatic diseasesInitiating Phase 1 study of AX-0810 in healthy volunteers, with initial safety, tolerability, and PK data from Cohort 1 expected by year-end, and target engagement data from all cohorts in H1 2026€ 106.9 million cash and cash equivalents as of end Q3 – providing runway into mid-2027 LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:</description>
</item>
<item>
<title>ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025</title>
<link>https://6ix.com/company/proqr-therapeutics-bv/news/proqr-receives-cta-authorization-for-ax-0810-and-announces-virtual-investor-and-analyst-event-on-november-3-2025</link>
<guid isPermaLink="true">https://6ix.com/company/proqr-therapeutics-bv/news/proqr-receives-cta-authorization-for-ax-0810-and-announces-virtual-investor-and-analyst-event-on-november-3-2025</guid>
<pubDate>Mon, 20 Oct 2025 04:00:00 GMT</pubDate>
<description>LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing</description>
</item>
<item>
<title>ProQR to Participate in Upcoming Investor Conferences in October 2025</title>
<link>https://6ix.com/company/proqr-therapeutics-bv/news/proqr-participate-upcoming-investor-conferences-123000426</link>
<guid isPermaLink="true">https://6ix.com/company/proqr-therapeutics-bv/news/proqr-participate-upcoming-investor-conferences-123000426</guid>
<pubDate>Mon, 13 Oct 2025 12:30:00 GMT</pubDate>
<description>LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology platform, today announced that company management will participate in the following upcoming investor conferences: H.C. Wainwright Genetic Medicines Virtual Conference – October 14-15, 2025Presentation available on demand beginning</description>
</item>
<item>
<title>ProQR Announces Second Quarter 2025 Operating and Financial Results</title>
<link>https://6ix.com/company/proqr-therapeutics-bv/news/proqr-announces-second-quarter-2025-110000636</link>
<guid isPermaLink="true">https://6ix.com/company/proqr-therapeutics-bv/news/proqr-announces-second-quarter-2025-110000636</guid>
<pubDate>Thu, 07 Aug 2025 11:00:00 GMT</pubDate>
<description>Submitted CTA for lead program AX-0810, targeting NTCP for cholestatic diseasesAdvancing AX-2402 program toward clinical candidate selection, targeting MECP2 (R270X) for Rett SyndromeHosting fall Analyst and Investor Event (virtual), featuring detailed AX-0810 Phase 1 trial design and 2025 data expectations, plus updates across differentiated liver and CNS pipeline€ 119.8 million cash and cash equivalents as of end Q2 – providing runway into mid-2027, not including additional potential milestone</description>
</item>
<item>
<title>ProQR Announces Upcoming Presentation at RNA Editing Summit</title>
<link>https://6ix.com/company/proqr-therapeutics-bv/news/proqr-announces-upcoming-presentation-rna-120000610</link>
<guid isPermaLink="true">https://6ix.com/company/proqr-therapeutics-bv/news/proqr-announces-upcoming-presentation-rna-120000610</guid>
<pubDate>Mon, 28 Jul 2025 12:00:00 GMT</pubDate>
<description>LEIDEN, Netherlands & CAMBRIDGE, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that it will participate in the RNA Editing Summit taking place July 29-31, 2025, in Boston, MA. “We recently achieved a key milestone with the submission of the CTA for AX-0810, targeting NTCP for cholestatic diseases, an</description>
</item>
<item>
<title>ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP</title>
<link>https://6ix.com/company/proqr-therapeutics-bv/news/proqr-announces-cta-submission-phase-203000118</link>
<guid isPermaLink="true">https://6ix.com/company/proqr-therapeutics-bv/news/proqr-announces-cta-submission-phase-203000118</guid>
<pubDate>Thu, 26 Jun 2025 20:30:00 GMT</pubDate>
<description>First-in-human trial of AX-0810 will evaluate safety, tolerability, pharmacokinetics, and target engagement in healthy volunteers with initial data expected in Q4 2025Marks the first submitted Clinical Trial Application (CTA) advancing ProQR’s Axiomer™ ADAR-mediated RNA editing platform into clinical development LEIDEN, Netherlands & CAMBRIDGE, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA t</description>
</item>
<item>
<title>ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences</title>
<link>https://6ix.com/company/proqr-therapeutics-bv/news/proqr-announces-upcoming-scientific-presentations-120000781</link>
<guid isPermaLink="true">https://6ix.com/company/proqr-therapeutics-bv/news/proqr-announces-upcoming-scientific-presentations-120000781</guid>
<pubDate>Mon, 12 May 2025 12:00:00 GMT</pubDate>
<description>LEIDEN, Netherlands & CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that it will present at two upcoming scientific conferences: the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting, taking place May 13-17, 2025, in New Orleans, Louisiana and the TIDES USA 2025: Oligonucl</description>
</item>
<item>
<title>ProQR Announces First Quarter 2025 Operating and Financial Results</title>
<link>https://6ix.com/company/proqr-therapeutics-bv/news/proqr-announces-first-quarter-2025-110000752</link>
<guid isPermaLink="true">https://6ix.com/company/proqr-therapeutics-bv/news/proqr-announces-first-quarter-2025-110000752</guid>
<pubDate>Thu, 08 May 2025 11:00:00 GMT</pubDate>
<description>Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Strengthened leadership with appointments of Chief Financial Officer and Chief Medical Officer€ 132.4 million cash and cash equivalents as of end Q1 providing runway into mid-2027, plus additional potential milestones from Lilly partnership LEIDEN, Netherlands & CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) --</description>
</item>
<item>
<title>ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference</title>
<link>https://6ix.com/company/proqr-therapeutics-bv/news/proqr-announces-webcast-presentation-2025-120000453</link>
<guid isPermaLink="true">https://6ix.com/company/proqr-therapeutics-bv/news/proqr-announces-webcast-presentation-2025-120000453</guid>
<pubDate>Fri, 02 May 2025 12:00:00 GMT</pubDate>
<description>LEIDEN, Netherlands & CAMBRIDGE, Mass., May 02, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform today announced that Company management is scheduled to present at the Citizens (JMP) Life Sciences Conference in New York City on Thursday, May 8 at 11:30 AM EDT. A live webcast of the Company’s fireside chat will be available from the “I</description>
</item>
<item>
<title>ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025</title>
<link>https://6ix.com/company/proqr-therapeutics-bv/news/proqr-announces-annual-general-meeting-120000275</link>
<guid isPermaLink="true">https://6ix.com/company/proqr-therapeutics-bv/news/proqr-announces-annual-general-meeting-120000275</guid>
<pubDate>Thu, 01 May 2025 12:00:00 GMT</pubDate>
<description>LEIDEN, Netherlands & CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the Annual General Meeting (AGM) of Shareholders will take place on Tuesday, June 3, 2025 at 1530 CEST at the offices of Allen Overy Shearman Sterling LLP, in Amsterdam, the Netherlands. All relevant documents and informa</description>
</item>
<item>
<title>ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth</title>
<link>https://6ix.com/company/proqr-therapeutics-bv/news/proqr-strengthens-leadership-appointments-cfo-110000986</link>
<guid isPermaLink="true">https://6ix.com/company/proqr-therapeutics-bv/news/proqr-strengthens-leadership-appointments-cfo-110000986</guid>
<pubDate>Mon, 14 Apr 2025 11:00:00 GMT</pubDate>
<description>LEIDEN, Netherlands & CAMBRIDGE, Mass., April 14, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the appointment of Dennis Hom as Chief Financial Officer (CFO) and Cristina Lopez Lopez, MD, PhD, as Chief Medical Officer (CMO). These key leadership appointments support the advancement of the Company’s Axiomer platfor</description>
</item>
<item>
<title>ProQR Announces Year End 2024 Operating and Financial Results</title>
<link>https://6ix.com/company/proqr-therapeutics-bv/news/proqr-announces-end-2024-operating-110000569</link>
<guid isPermaLink="true">https://6ix.com/company/proqr-therapeutics-bv/news/proqr-announces-end-2024-operating-110000569</guid>
<pubDate>Thu, 13 Mar 2025 11:00:00 GMT</pubDate>
<description>Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Company expects up to four clinical data readouts in 2025 and 2026 across multiple programs, highlighted by first clinical data for AX-0810 anticipated in Q4 2025€ 149.4 million cash and cash equivalents as of end of 2024, providing runway into mid-2027, plus additional potential milestones from Lilly partnershi</description>
</item>
<item>
<title>ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration</title>
<link>https://6ix.com/company/proqr-therapeutics-bv/news/proqr-therapeutics-announces-dollar81-million-in-new-funding-from-rett-syndrome-research-trust-to-expand-rna-editing-collaboration</link>
<guid isPermaLink="true">https://6ix.com/company/proqr-therapeutics-bv/news/proqr-therapeutics-announces-dollar81-million-in-new-funding-from-rett-syndrome-research-trust-to-expand-rna-editing-collaboration</guid>
<pubDate>Wed, 11 Dec 2024 05:00:00 GMT</pubDate>
<description>LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 11, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives</description>
</item>
</channel>
</rss>